Cooper Companies (NASDAQ:COO) Releases FY25 Earnings Guidance

Cooper Companies (NASDAQ:COO) issued an update on its FY25 earnings guidance on Thursday morning. The company provided EPS guidance of $3.92-$4.02 for the period, compared to the consensus EPS estimate of $4.06. The company issued revenue guidance of $4.080-$4.158 billion, compared to the consensus revenue estimate of $4.19 billion.

Cooper Companies Stock Down 1.7 %

COO stock traded down $1.75 during midday trading on Thursday, reaching $103.23. 1,842,913 shares of the company were exchanged, compared to its average volume of 1,140,510. The company has a market cap of $20.56 billion, a price-to-earnings ratio of 57.81, a price-to-earnings-growth ratio of 2.24 and a beta of 0.97. Cooper Companies has a 1-year low of $82.69 and a 1-year high of $112.38. The stock’s 50-day simple moving average is $104.84 and its 200 day simple moving average is $98.74. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.18 and a current ratio of 1.99.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings data on Thursday, December 5th. The medical device company reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.04. Cooper Companies had a net margin of 9.45% and a return on equity of 9.08%. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.03 billion. During the same quarter in the prior year, the company posted $0.87 EPS. The company’s quarterly revenue was up 9.8% compared to the same quarter last year. On average, equities analysts forecast that Cooper Companies will post 3.65 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. StockNews.com raised Cooper Companies from a “hold” rating to a “buy” rating in a research report on Tuesday. Piper Sandler increased their target price on Cooper Companies from $115.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday, August 29th. Needham & Company LLC reaffirmed a “hold” rating on shares of Cooper Companies in a research report on Wednesday, November 27th. Robert W. Baird raised their price target on Cooper Companies from $118.00 to $125.00 and gave the company an “outperform” rating in a report on Thursday, August 29th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $115.00 price target (up from $110.00) on shares of Cooper Companies in a report on Thursday, August 29th. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat, Cooper Companies currently has a consensus rating of “Moderate Buy” and an average target price of $117.00.

Insider Transactions at Cooper Companies

In related news, CAO Agostino Ricupati sold 1,601 shares of the business’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $108.03, for a total value of $172,956.03. Following the sale, the chief accounting officer now owns 4,818 shares of the company’s stock, valued at $520,488.54. The trade was a 24.94 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Albert G. White III sold 114,992 shares of the business’s stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $110.53, for a total value of $12,710,065.76. Following the completion of the sale, the chief executive officer now directly owns 165,273 shares in the company, valued at approximately $18,267,624.69. This represents a 41.03 % decrease in their position. The disclosure for this sale can be found here. 2.00% of the stock is owned by insiders.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.